Foley Mark J — SEC Form 4 filings
SEC reporting owner CIK 1529196. 15 Form 4 filings on record with FilingPulse; latest filed 2026-06-23.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-02-02 to 2026-06-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 30,000 shares, $209,400 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 25,247 shares, $2,920,822 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 27.
- Largest priced transaction: sale of 20,687 shares @ $120.72 ($2,497,335) in GLAUKOS Corp, filed 2025-02-28.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| GLAUKOS Corp (GKOS) | Director | 7 | — | 2 legs · 25,247 sh · $2,920,822 | 15 |
| Revance Therapeutics, Inc. (RVNC) | President & CEO, Director | 8 | 1 leg · 30,000 sh · $209,400 | — | 12 |
Form 4 filings — Foley Mark J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-23 | 4/A | GLAUKOS Corp (GKOS) | Grant/award (A): 2,987 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 1,878 @ $0 · Grant/award (A): 2,987 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 1,168 @ $0 | EDGAR |
| 2025-06-02 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 864 @ $0 · Grant/award (A): 2,108 @ $0 · Grant/award (A): 3,149 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | GLAUKOS Corp (GKOS) | Option exercise (M): 25,000 @ $32 · Option exercise (M): 15,000 @ $24.69 · Sale (S): 20,687 @ $120.72 · Option exercise (M): 25,000 (derivative) @ $0 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Revance Therapeutics, Inc. (RVNC) | Code (U): 996,935 @ $3.65 · Code (U): 110,913 @ $3.65 · Disposition to issuer (D): 27,933 · Grant/award (A): 84,686 @ $0 · Disposition to issuer (D): 84,686 | EDGAR |
| 2025-02-05 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 27,933 @ $0 | EDGAR |
| 2025-01-03 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 1,000 @ $2.18 | EDGAR |
| 2024-07-02 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 1,000 @ $2.18 | EDGAR |
| 2024-06-03 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 1,716 @ $0 · Grant/award (A): 1,246 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Revance Therapeutics, Inc. (RVNC) | Tax withholding (F): 3,305 @ $5.30 · Tax withholding (F): 17,228 @ $5.30 | EDGAR |
| 2024-03-08 | 4 | Revance Therapeutics, Inc. (RVNC) | Purchase (P): 30,000 @ $6.98 | EDGAR |
| 2024-03-04 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 70,750 @ $0 | EDGAR |
| 2024-02-26 | 4 | GLAUKOS Corp (GKOS) | Option exercise (M): 10,000 @ $7.28 · Sale (S): 4,560 @ $92.87 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 1,070,001 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1529196 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →